Cantor Fitzgerald Issues Positive Estimate for TARA Earnings

Key Points

• Cantor Fitzgerald has raised its FY2025 earnings estimates for Protara Therapeutics, now expecting a loss of ($1.40) per share, improved from a previous forecast of ($1.71).
• Protara Therapeutics reported quarterly earnings of ($0.35) per share, exceeding analysts' expectations of ($0.43) by $0.08.
• Institutional investors have significantly increased their stake in Protara, with hedge funds owning 38.13% of the company’s stock, indicating growing interest and confidence in the firm.

Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for shares of Protara Therapeutics in a research note issued to investors on Monday, August 18th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will post earnings per share of ($1.40) for the year, up from their previous estimate of ($1.71). The consensus estimate for Protara Therapeutics' current full-year earnings is ($3.32) per share. Cantor Fitzgerald also issued estimates for Protara Therapeutics' FY2026 earnings at ($1.50) EPS.

Several other brokerages also recently commented on TARA. Jones Trading upgraded shares of Protara Therapeutics to a "strong-buy" rating and set a $21.00 target price on the stock in a research note on Thursday, May 22nd. HC Wainwright reaffirmed a "buy" rating and set a $23.00 price target on shares of Protara Therapeutics in a report on Monday, April 28th. One analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $19.60.

Protara Therapeutics Trading Up 0.3%

NASDAQ:TARA traded up $0.01 during mid-day trading on Wednesday, hitting $3.11. The company's stock had a trading volume of 222,847 shares, compared to its average volume of 202,352. Protara Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $10.48. The stock has a fifty day moving average of $3.10 and a 200-day moving average of $3.55. The company has a market capitalization of $119.99 million, a price-to-earnings ratio of -1.92 and a beta of 1.42.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.08.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TARA. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Protara Therapeutics during the 2nd quarter worth approximately $30,000. Quadrature Capital Ltd acquired a new position in Protara Therapeutics in the second quarter valued at about $35,000. JPMorgan Chase & Co. acquired a new position in shares of Protara Therapeutics in the 2nd quarter valued at approximately $46,000. Los Angeles Capital Management LLC bought a new stake in shares of Protara Therapeutics during the second quarter worth $47,000. Finally, Intech Investment Management LLC bought a new position in Protara Therapeutics during the 2nd quarter worth about $49,000. Institutional investors and hedge funds own 38.13% of the company's stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.